MedTrace Logo

Women's Assessed Cardiovascular Evaluation With MCG

NCT04739280 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2023-02-23

No results posted yet for this study

Summary

Cardiovascular disease (CVD) is the number one cause of death for women over the age of 25, accounting for 1 of every 3 female deaths. Research has shown that while hypertension in women is less controlled, they are also less likely to be identified with ischemic heart disease and when diagnosed treated less aggressively than men. Moreover, women who are diagnosed with breast cancer have an increased risk for cardiovascular disease. The Women's Assessed Cardiovascular Evaluation with MCG (WACE-MCG) study is designed to collect CardioFlux scans on a select group of female volunteers who are Ms. Medicine patients. CardioFlux is used as a noninvasive MCG tool that analyzes and records the magnetic fields of the heart to detect various forms of heart disease. There will be a 12-month duration of the study where we propose to collect screening data from approximately 200 volunteers who present to the Genetesis facility for a 5-minute CardioFlux MCG scan. The volunteers will be contacted at intervals over a 1-year period for follow-up data and may choose whether or not they would like to provide follow-up data or participate in another scan.

Conditions

  • Ischemia
  • Cardiac Disease
  • Risk Factor, Cardiovascular

Interventions

DEVICE

CardioFlux Magnetocardiography

Magnetocardiography

Sponsors & Collaborators

  • Genetesis Inc.

    lead INDUSTRY

Principal Investigators

  • Anthony Senagore, M.D. · Genetesis Inc.

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2022-07-21
Completion
2022-07-21
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04739280 on ClinicalTrials.gov